A distinct clinicopathological presentation of cutaneous dermatophytosis mimicking autoimmune blistering disorder

Padhiyar, Jignaben Krunal; Patel, Nayankumar Harshadkumar; Gajjar, Trusha; Patel, Bhagirath; Chhibber, Aseem; Buch, Mansi D

doi:10.4103/ijd.ijd_143_18

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bullous pemphigoid (BP), which manifests subepidermal skin lesions with bulla formation, is increasing in prevalence and has high mortality worldwide 2,3 . Evidence in recent years has indicated that BP is associated with malignancy, drugs, systemic lupus erythematosus, scleroderma, and psoriasis 4 …”

Section: Introductionmentioning

confidence: 99%

“…2,3 Evidence in recent years has indicated that BP is associated with malignancy, drugs, systemic lupus erythematosus, scleroderma, and psoriasis. 4 Antibodies against two hemidesmosome proteins of the dermal-epidermal junction, BP180 (collagen XVII) and BP230, might be the leading events in blister formation in BP. 5 Recent studies have also identified the important pathogenic mechanisms of IgE class autoantibodies in autoimmune skin diseases targeting BP180.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of biological agents for pemphigoid: a systematic review and meta‐analysis

et al. 2023

View full text Add to dashboard Cite

Biologic agents (also termed biologics) have become an important adjuvant‐targeted treatment option in autoimmune blistering disease. We evaluated the efficacy and safety of newly licensed biologics for the management of pemphigoid using a meta‐analysis. PubMed, EMBASE, Web of Science, and the Cochrane Library for studies involving pemphigoid patients treated with biological agents (rituximab, dupilumab, omalizumab, or mepolizumab) were searched. The pooled risk ratio (RR) with a 95% confidence interval (CI) was used to assess the short‐term efficacy, adverse event (AE), relapse, and long‐term survival. A total of seven studies involving 296 patients were identified. The pooled RRs for short‐term effectiveness, AE, relapse, and long‐term survival rate in patients treated with biological agents versus systemic corticosteroids were 1.37 (95% CI 0.95–1.97; I2 = 82%; P = 0.09), 0.54 (95% CI 0.39–0.73; I2 = 13%; P = 0.005), 1.36 (95% CI 0.95–1.96; I2 = 16.8%; P = 0.19), and 1.08 (95% CI 0.95–1.21; I2 = 48.1%; P = 0.53), respectively. Meta‐regression and subgroup analysis revealed that the RRs of efficacy were 2.10 (95% CI 1.61–2.75; I2 = 0%; P < 0.00001) for rituximab and 2.07 (95% CI 1.61–2.67; I2 = 0%; P < 0.00001) for sample size greater than 30. Compared with conventional therapy, biologics treatment was significantly associated with fewer adverse events (P < 0.05), but no significant differences were found for efficacy and relapse (P > 0.05). The findings demonstrate that a biologics‐containing regimen could minimize the occurrence of AEs and might display a comparable efficacy and recurrence to that of receiving systemic corticosteroids.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of biological agents for pemphigoid: a systematic review and meta‐analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…We read with great interest the article, “A distinct clinicopathological presentation of cutaneous dermatophytosis mimicking autoimmune blistering disorder” which appeared in the Indian Journal of Dermatology, Issue 5, Volume 63. [1]…”

mentioning

confidence: 99%